Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1428
Peer-review started: April 30, 2021
First decision: June 17, 2021
Revised: June 23, 2021
Accepted: September 3, 2021
Article in press: September 3, 2021
Published online: October 27, 2021
Processing time: 175 Days and 1.7 Hours
There is a continuous interest in genotype-phenotype correlations in Wilson’s disease (WD).
The aim is to study the possible genotype-phenotype correlations in children with acute liver failure (ALF) and hemolytic anemia in WD.
The objectives include the analysis of ATP7B variants in children with ALF and hemolytic anemia in WD compared to the other clinical presentations and the possible role of the HSD17B13:TA variant in the modulation of the WD severity.
The retrospective study included 63 children with WD diagnosed and follow-up during 2006-2020. The clinical manifestations (acute or chronic liver disease, neurologic disease, ALF with non-immune hemolytic anemia), laboratory parameters, copper metabolism, ATP7B variants, and the HSD17B13:TA (rs72613567) variant were reviewed.
In our cohort, in children with ALF and non-immune hemolytic anemia, the nonsense variants other than p.His1069Gln (c.3206A>G), as p.Trp939Cys (c.2817G>T), and frame-shift variants, as p.Lys844Ter (c.2530A>T), were the most frequently present. The allele frequency of HSD17B13:TA was similar to other results for the Caucasian population, higher in patients with the less severe liver disease than those presented with ALF and hemolytic anemia.
It remains challenging to prove a genotype-phenotype correlation in WD patients due to the small number of patients in the reported series and the increased genetic heterogeneity. When nonsense, frame-shift, or splicing-site variants are identified in a pre-symptomatic period, the importance of this genotype-phenotype correlation for the prognostic is evident.
A more extensive study involving children and adolescents with ALF and hemolytic anemia form of WD should be provided to confirm the findings. New studies are needed to evaluate the role of protective variant, HSD17B13:TA (rs72613567), in association with other factors, in less severe forms of WD in children.